-$0.67 Earnings Per Share Expected for Autolus Therapeutics Ltd – (NASDAQ:AUTL) This Quarter

Analysts expect Autolus Therapeutics Ltd – (NASDAQ:AUTL) to post ($0.67) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Autolus Therapeutics’ earnings. The highest EPS estimate is ($0.60) and the lowest is ($0.73). Autolus Therapeutics posted earnings per share of ($0.65) during the same quarter last year, which would indicate a negative year-over-year growth rate of 3.1%. The company is scheduled to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Autolus Therapeutics will report full-year earnings of ($2.77) per share for the current fiscal year, with EPS estimates ranging from ($2.97) to ($2.40). For the next financial year, analysts forecast that the firm will report earnings of ($3.14) per share, with EPS estimates ranging from ($4.00) to ($2.36). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Autolus Therapeutics.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Thursday, May 7th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.14. The company had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $1.15 million. Autolus Therapeutics had a negative return on equity of 45.59% and a negative net margin of 9,870.67%.

Several brokerages recently weighed in on AUTL. Zacks Investment Research upgraded Autolus Therapeutics from a “hold” rating to a “strong-buy” rating and set a $12.00 target price for the company in a report on Tuesday, May 12th. BidaskClub upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. Needham & Company LLC started coverage on Autolus Therapeutics in a report on Monday, June 1st. They set a “buy” rating and a $26.00 target price for the company. Mizuho reaffirmed a “buy” rating and set a $18.00 price target on shares of Autolus Therapeutics in a research report on Friday, May 29th. Finally, William Blair reaffirmed a “buy” rating on shares of Autolus Therapeutics in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Autolus Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $20.00.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AUTL. Citigroup Inc. raised its position in shares of Autolus Therapeutics by 194.9% in the 4th quarter. Citigroup Inc. now owns 2,041 shares of the company’s stock worth $27,000 after acquiring an additional 1,349 shares in the last quarter. Legal & General Group Plc raised its position in shares of Autolus Therapeutics by 31.5% in the 1st quarter. Legal & General Group Plc now owns 4,623 shares of the company’s stock worth $27,000 after acquiring an additional 1,108 shares in the last quarter. Tower Research Capital LLC TRC bought a new position in shares of Autolus Therapeutics in the 4th quarter worth approximately $29,000. Advisor Group Holdings Inc. bought a new position in shares of Autolus Therapeutics in the 1st quarter worth approximately $46,000. Finally, Burrage Capital Management LLC raised its position in shares of Autolus Therapeutics by 14.4% in the 1st quarter. Burrage Capital Management LLC now owns 15,006 shares of the company’s stock worth $84,000 after acquiring an additional 1,893 shares in the last quarter. 38.12% of the stock is owned by institutional investors and hedge funds.

AUTL stock traded down $0.07 during trading on Monday, hitting $12.92. 480,651 shares of the company traded hands, compared to its average volume of 154,372. Autolus Therapeutics has a 1 year low of $3.00 and a 1 year high of $19.34. The company has a 50-day moving average of $11.10 and a 200-day moving average of $10.52. The company has a current ratio of 10.78, a quick ratio of 10.78 and a debt-to-equity ratio of 0.08.

About Autolus Therapeutics

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Further Reading: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on Autolus Therapeutics (AUTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.